Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25067818 | 0.82 | SMN1; SMN2 (0.45) | ATMLMNASMN1; SMN2ALDH1A1PKM | |
| SCHEMBL13282805 | 0.81 | — | — | |
| SCHEMBL13282806 | 0.81 | — | — | |
| SCHEMBL6991664 | 0.81 | — | — | |
| SCHEMBL13285189 | 0.75 | DPP8 (0.46) | ATMLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL23012687 | 0.75 | ATM (0.50) | ATMLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9616431 | 0.74 | SMN1; SMN2 (0.40) | ATMLMNASMN1; SMN2ALDH1A1PKM | |
| SCHEMBL417121 | 0.71 | SMN1; SMN2 (0.40) | ATMLMNASMN1; SMN2ALDH1A1PKM | |
| SCHEMBL10100337 | 0.71 | SMN1; SMN2 (0.38) | ATMLMNASMN1; SMN2ALDH1A1PKM | |
| SCHEMBL9459164 | 0.70 | ATM (0.38) | ATMLMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3908306-A1 | PHOSPHATASE BINDING COMPOUNDS AND METHODS OF USING SAME | Yale University (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | YALE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| WO-2020146470-A1 | Phosphatase Binding Compounds and Methods of Using Same | YALE UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | PPP5C, PPP4C, DUSP26 | ATM 728/4885LMNA 4621/4885HTT 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.